Medications for Chronic Kidney Disease
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Chronic Kidney Disease.
Found 12 Approved Drugs for Chronic Kidney Disease
Calcitriol
Brand Names
Calcitrol, Rocaltrol, Vectical
Calcitriol
Brand Names
Calcitrol, Rocaltrol, Vectical
Form: Ointment, Injection, Capsule, Solution
Method of administration: Oral, Intravenous, Topical
FDA approval date: July 18, 2003
Classification: Vitamin D3 Analog
Predialysis Patients Calcitriol capsules re indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of.
MetFORMIN
Brand Names
Glyburide-MetFORMIN, Janumet, Saxagliptin, Zituvimet, Invokamet, Pioglitazole, Sitagliptin, Segluromet, Actoplus, Riomet, Glumetza, Jentadueto, Xigduo, Trijardy, Pioglitazone, MetFORMIN Hydrochoride, Alogliptin, Kombiglyze, Dapagliflozin, Glipizide, Glyburide, Synjardy, Kazano
MetFORMIN
Brand Names
Glyburide-MetFORMIN, Janumet, Saxagliptin, Zituvimet, Invokamet, Pioglitazole, Sitagliptin, Segluromet, Actoplus, Riomet, Glumetza, Jentadueto, Xigduo, Trijardy, Pioglitazone, MetFORMIN Hydrochoride, Alogliptin, Kombiglyze, Dapagliflozin, Glipizide, Glyburide, Synjardy, Kazano
Form: Tablet, Solution
Method of administration: Oral
FDA approval date: January 24, 2002
Classification: Dipeptidyl Peptidase 4 Inhibitor
Metformin hydrochloride extended-release tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin hydrochloride is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 )
Carnitor
Generic Name
Levocarnitine
Carnitor
Generic Name
Levocarnitine
Form: Injection, Tablet, Solution
Method of administration: Oral, Intravenous
FDA approval date: December 27, 1985
Classification: Carnitine Analog
Levocarnitine Oral Solution USP is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation. In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine Oral Solution USP is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. CONTRAINDICATIONS None known.
Rayaldee
Generic Name
Calcifediol
Rayaldee
Generic Name
Calcifediol
Form: Capsule
Method of administration: Oral
FDA approval date: October 25, 2016
Classification: Vitamin D3 Analog
RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Limitations of Use RAYALDEE is not indicated for the treatment of secondary hyperparathyroidism in patients with stage 5 chronic kidney disease or in patients with end-stage renal disease on dialysis. RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. ( 1 ) Limitations of Use: RAYALDEE is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis. ( 1 )
Irbesartan
Brand Names
Avapro, Avalide
Irbesartan
Brand Names
Avapro, Avalide
Form: Tablet
Method of administration: Oral
FDA approval date: September 27, 2012
Classification: Angiotensin 2 Receptor Blocker
Irbesartan USP is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Showing 1-5 of 12
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances